vs
Nurix Therapeutics, Inc.（NRIX）与Rent the Runway, Inc.（RENT）财务数据对比。点击上方公司名可切换其他公司
Nurix Therapeutics, Inc.的季度营收约是Rent the Runway, Inc.的1.3倍（$13.6M vs $10.6M），Rent the Runway, Inc.净利率更高（721.7% vs -576.1%，领先1297.8%），Rent the Runway, Inc.同比增速更快（10.4% vs 2.2%），过去两年Rent the Runway, Inc.的营收复合增速更高（1.0% vs -9.5%）
Nurix Therapeutics是一家临床阶段生物制药企业，专注于发现、开发及商业化针对癌症、免疫疾病等存在重大未满足医疗需求的新型靶向蛋白降解疗法，依托专有的E3泛素连接酶调节技术推进管线研发，与全球多家制药企业达成合作。
Rent the Runway Inc.是总部位于纽约的美国电商平台，由珍妮弗·海曼与珍妮弗·弗莱斯于2009年11月创立，主打设计师品牌服饰与配饰的租赁、订阅以及购买服务，是设计师服饰共享租赁模式的开创平台之一。
NRIX vs RENT — 直观对比
营收规模更大
NRIX
是对方的1.3倍
$10.6M
营收增速更快
RENT
高出8.2%
2.2%
净利率更高
RENT
高出1297.8%
-576.1%
两年增速更快
RENT
近两年复合增速
-9.5%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $13.6M | $10.6M |
| 净利润 | $-78.2M | $76.5M |
| 毛利率 | — | -126.4% |
| 营业利润率 | -612.0% | -152.8% |
| 净利率 | -576.1% | 721.7% |
| 营收同比 | 2.2% | 10.4% |
| 净利润同比 | -33.6% | 504.8% |
| 每股收益（稀释后） | $-0.83 | $13.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NRIXRENT
| Q4 25 | $13.6M | $10.6M | ||
| Q3 25 | $7.9M | $11.7M | ||
| Q2 25 | $44.1M | $7.6M | ||
| Q1 25 | $18.5M | $11.8M | ||
| Q4 24 | $13.3M | $9.6M | ||
| Q3 24 | $12.6M | $10.4M | ||
| Q2 24 | $12.1M | $8.9M | ||
| Q1 24 | $16.6M | $10.4M |
净利润NRIXRENT
| Q4 25 | $-78.2M | $76.5M | ||
| Q3 25 | $-86.4M | $-26.4M | ||
| Q2 25 | $-43.5M | $-26.1M | ||
| Q1 25 | $-56.4M | $-13.4M | ||
| Q4 24 | $-58.5M | $-18.9M | ||
| Q3 24 | $-49.0M | $-15.6M | ||
| Q2 24 | $-44.5M | $-22.0M | ||
| Q1 24 | $-41.5M | $-24.8M |
毛利率NRIXRENT
| Q4 25 | — | -126.4% | ||
| Q3 25 | — | -92.3% | ||
| Q2 25 | — | -168.4% | ||
| Q1 25 | — | -71.2% | ||
| Q4 24 | — | -122.9% | ||
| Q3 24 | — | -98.1% | ||
| Q2 24 | — | -131.5% | ||
| Q1 24 | — | -93.3% |
营业利润率NRIXRENT
| Q4 25 | -612.0% | -152.8% | ||
| Q3 25 | -1157.7% | -171.8% | ||
| Q2 25 | -109.7% | -259.2% | ||
| Q1 25 | -340.7% | -65.3% | ||
| Q4 24 | -486.7% | -142.7% | ||
| Q3 24 | -433.8% | -92.3% | ||
| Q2 24 | -401.4% | -185.4% | ||
| Q1 24 | -272.6% | -185.6% |
净利率NRIXRENT
| Q4 25 | -576.1% | 721.7% | ||
| Q3 25 | -1094.8% | -225.6% | ||
| Q2 25 | -98.7% | -343.4% | ||
| Q1 25 | -305.4% | -113.6% | ||
| Q4 24 | -440.7% | -196.9% | ||
| Q3 24 | -388.9% | -150.0% | ||
| Q2 24 | -368.4% | -247.2% | ||
| Q1 24 | -250.3% | -238.5% |
每股收益（稀释后）NRIXRENT
| Q4 25 | $-0.83 | $13.65 | ||
| Q3 25 | $-1.03 | $-6.55 | ||
| Q2 25 | $-0.52 | $-6.58 | ||
| Q1 25 | $-0.67 | $-2.72 | ||
| Q4 24 | $-0.74 | $-4.70 | ||
| Q3 24 | $-0.67 | $-4.17 | ||
| Q2 24 | $-0.71 | $-6.03 | ||
| Q1 24 | $-0.76 | $-5.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $247.0M | $50.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $538.7M | $-35.1M |
| 总资产 | $688.1M | $231.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NRIXRENT
| Q4 25 | $247.0M | $50.7M | ||
| Q3 25 | $78.4M | $43.6M | ||
| Q2 25 | $84.3M | $70.4M | ||
| Q1 25 | $75.9M | $77.4M | ||
| Q4 24 | $110.0M | $74.1M | ||
| Q3 24 | $99.0M | $76.6M | ||
| Q2 24 | $116.8M | $82.0M | ||
| Q1 24 | $49.8M | $84.0M |
总债务NRIXRENT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $340.6M | ||
| Q1 25 | — | $333.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益NRIXRENT
| Q4 25 | $538.7M | $-35.1M | ||
| Q3 25 | $372.3M | $-232.1M | ||
| Q2 25 | $447.6M | $-207.1M | ||
| Q1 25 | $480.9M | $-182.5M | ||
| Q4 24 | $527.0M | $-171.2M | ||
| Q3 24 | $376.9M | $-154.5M | ||
| Q2 24 | $370.7M | $-141.3M | ||
| Q1 24 | $168.7M | $-122.3M |
总资产NRIXRENT
| Q4 25 | $688.1M | $231.0M | ||
| Q3 25 | $522.5M | $219.0M | ||
| Q2 25 | $591.6M | $245.3M | ||
| Q1 25 | $615.0M | $240.0M | ||
| Q4 24 | $669.3M | $251.6M | ||
| Q3 24 | $513.6M | $257.4M | ||
| Q2 24 | $511.0M | $278.4M | ||
| Q1 24 | $312.7M | $278.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-67.8M | $-1.4M |
| 自由现金流经营现金流 - 资本支出 | $-73.0M | — |
| 自由现金流率自由现金流/营收 | -537.4% | — |
| 资本支出强度资本支出/营收 | 37.8% | — |
| 现金转化率经营现金流/净利润 | — | -0.02× |
| 过去12个月自由现金流最近4个季度 | $-263.5M | — |
8季度趋势，按日历期对齐
经营现金流NRIXRENT
| Q4 25 | $-67.8M | $-1.4M | ||
| Q3 25 | $-57.4M | $-10.5M | ||
| Q2 25 | $-63.2M | $8.3M | ||
| Q1 25 | $-61.1M | $1.4M | ||
| Q4 24 | $-48.8M | $4.7M | ||
| Q3 24 | $-42.2M | $2.2M | ||
| Q2 24 | $-39.7M | $4.6M | ||
| Q1 24 | $-42.0M | $-8.0M |
自由现金流NRIXRENT
| Q4 25 | $-73.0M | — | ||
| Q3 25 | $-60.1M | — | ||
| Q2 25 | $-65.8M | — | ||
| Q1 25 | $-64.6M | — | ||
| Q4 24 | $-50.9M | — | ||
| Q3 24 | $-44.5M | — | ||
| Q2 24 | $-41.6M | — | ||
| Q1 24 | $-44.8M | — |
自由现金流率NRIXRENT
| Q4 25 | -537.4% | — | ||
| Q3 25 | -761.3% | — | ||
| Q2 25 | -149.4% | — | ||
| Q1 25 | -349.9% | — | ||
| Q4 24 | -382.8% | — | ||
| Q3 24 | -353.7% | — | ||
| Q2 24 | -344.4% | — | ||
| Q1 24 | -270.3% | — |
资本支出强度NRIXRENT
| Q4 25 | 37.8% | — | ||
| Q3 25 | 34.3% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 18.9% | — | ||
| Q4 24 | 15.8% | — | ||
| Q3 24 | 18.6% | — | ||
| Q2 24 | 16.0% | — | ||
| Q1 24 | 17.4% | — |
现金转化率NRIXRENT
| Q4 25 | — | -0.02× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NRIX
| Pfizer | $11.9M | 88% |
| Gilead Agreement | $1.7M | 13% |
RENT
暂无分部数据
